Why Is Compass Therapeutics (CMPX) Stock Down -62% Today?
Key Takeaways
- CMPX shares are plunging approximately 62% in Monday's session, collapsing to roughly $1.98 from a prior close of $5.21 on April 24, 2026.
- The primary catalyst is the presentation of topline secondary endpoint data from the Phase 2/3 COMPANION-002 trial of tovecimig (CTX-009) plus paclitaxel in advanced biliary tract cancer, widely interpreted as disappointing.
- The move follows a pre-event run-up over the prior week as traders positioned for the April 27 webcast, amplifying the reversal.
- The decline extends a pattern of clinical data setbacks for tovecimig; prior data releases also triggered sharp double-digit drawdowns.
- Compass Therapeutics remains a pre-commercial biotech with minimal revenue and ongoing operating losses, making it entirely dependent on clinical catalysts.
- Traders are watching whether management issues additional commentary on the trial data and what the path forward looks like for the tovecimig program.
Opening Summary
Compass Therapeutics, Inc. (NASDAQ: CMPX) is a Boston-based clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics for cancer treatment. Its lead program, tovecimig (formerly CTX-009), is a bispecific antibody targeting DLL4 and VEGF-A signaling pathways in solid tumors. The company also has earlier-stage programs in CD137 agonism and PD-1/PD-L1 checkpoint inhibition.
On Monday, April 27, 2026, CMPX shares are crashing approximately 62% to roughly $1.98, reversing sharply from Friday's close of $5.21. The immediate driver is the release of topline secondary endpoint data from the Phase 2/3 COMPANION-002 study, presented during a company webcast this morning. The market's reaction signals that the secondary endpoint readout — covering progression-free survival (PFS) and overall survival (OS) — failed to demonstrate the magnitude of clinical benefit necessary to support continued investor confidence in the program.
Clinical Trial Data Disappointment
The COMPANION-002 trial is a randomized Phase 2/3 study evaluating tovecimig in combination with paclitaxel versus paclitaxel alone as second-line therapy for unresectable, advanced, or metastatic biliary tract cancer. The primary endpoint is Overall Response Rate (ORR), with PFS and OS as key secondary endpoints. Study enrollment had already closed prior to today's readout.
Today's webcast specifically highlighted topline secondary endpoint data — a framing that indicated the primary endpoint results had already been disclosed and were insufficient on their own to move the program forward. The secondary endpoint data appears to have confirmed market concerns about the drug's ability to deliver a meaningful survival benefit, triggering an immediate and severe price reaction. This pattern is consistent with prior tovecimig readouts; a previous data release showed an ORR of only 17.1% in Western patients, which underperformed competing second-line treatments in biliary tract cancer, and triggered a similar sharp sell-off.
Failed Bull Case and Pre-Event Positioning Unwind
In the days leading up to today's webcast, CMPX shares climbed approximately 8.25% on April 24 alone, closing near $5.21 as traders accumulated positions ahead of the clinical catalyst. The stock had staged a recovery from lows near $4.90 intraday, suggesting active accumulation in anticipation of a positive data surprise.
That pre-event positioning is now unwinding entirely. When a binary clinical catalyst disappoints, the reversal tends to be proportional to the run-up that preceded it, and it often extends further as stop-loss orders, forced selling, and momentum-driven exits compound the move. The result is the kind of catastrophic single-session collapse seen with small-cap biotechs when pivotal data fails to meet investor expectations.
Fundamental Backdrop and Balance Sheet Risk
The severity of the selloff reflects just how heavily CMPX's valuation depended on tovecimig's commercial potential. The company reported only approximately $850,000 in trailing twelve-month revenue, with a net loss that widened to approximately $66.5 million in its most recent fiscal year — a 35% increase in losses despite earlier clinical progress. Research and development expenses of approximately $13.7 million per quarter and G&A costs of roughly $4.3 million per quarter continue to consume cash at a significant pace.
With the COMPANION-002 secondary data failing to deliver the needed validation, questions now surround the company's capital runway and whether management will need to raise additional equity at deeply discounted prices to fund operations and the remaining pipeline programs, including CTX-8371 and CTX-10726.
Market Context and Trading Activity
Trading volume in CMPX has surged well above its average daily volume of approximately 2.4 million shares, driven overwhelmingly by institutional and retail exits following the morning webcast. The broader NASDAQ and healthcare sector ETFs such as XBI have not moved in a correlated direction, confirming the selloff is entirely company-specific and clinical-trial-driven rather than a macro or sector-wide event.
From a technical standpoint, the stock has broken through all meaningful near-term support levels and is trading in territory not seen since its 52-week low of $1.67, suggesting the market is repricing the company as a pipeline in need of a major strategic reassessment.
Trending AI Robots
For traders navigating high-volatility biotech events like today's CMPX collapse, Tickeron's Trending AI Robots page provides a curated view of the platform's top-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers, each differing in strategy, timeframe, risk tolerance, and traded symbols — but only the bots demonstrating the strongest live performance are elevated to the Trending section. Whether the focus is momentum trading, mean-reversion, or swing strategies across biotech or other sectors, the Trending AI Robots page offers a systematic, data-driven starting point for investors seeking to complement their research with algorithmic tools.
What Comes Next for CMPX
The immediate focus will be on management's formal written response to the COMPANION-002 secondary endpoint data and whether they provide additional statistical context, subgroup analyses, or a path forward for the tovecimig program. The company's next earnings report will draw close attention to cash and equivalents on the balance sheet, which will determine how long operations can continue under the current burn rate without additional financing.
Longer-term, investor attention will shift to earlier-stage assets: CTX-8371 (PD-1/PD-L1 bispecific), which has shown early signals in triple-negative breast cancer and Hodgkin lymphoma, and CTX-10726 (PD-1 x VEGF-A bispecific), which entered Phase 1 in early 2026. However, given the collapse in equity value, the company may face difficult decisions regarding prioritization of its pipeline and capital allocation. Any equity raise in the near term would represent significant dilution to current shareholders at deeply distressed prices.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for CMPX shows an upward move is likely
CMPX's Aroon Indicator triggered a bullish signal on June 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CMPX's RSI Oscillator exited the oversold zone, of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where CMPX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on CMPX as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CMPX broke above its upper Bollinger Band on May 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.028) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CMPX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (555.556) is also within normal values, averaging (366.957).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement